Revolution Medicines’ Daraxonrasib Wins FDA Approval as Rasonque: What the RAS Breakthrough Means for RVMD Investors

Revolution Medicines’ Daraxonrasib Wins FDA Approval as Rasonque: What the RAS Breakthrough Means for RVMD Investors

Updated from an earlier version published before Rasonque received FDA approval, with new clinical, regulatory, and investment information. 

For decades, one of cancer research’s most important targets was also one of its most frustrating. Scientists had known for years that a broken internal signal—something that tells cells to keep growing when they should stop—was driving many cancers, especially pancreatic cancer. The problem wasn’t understanding what was going wrong. It was that nobody could design a medicine that effectively fixed it. The protein responsible, called RAS, was long described as “undruggable”—not because it was mysterious, but because its surface offered few of the deep, stable pockets that conventional small-molecule drugs generally use to attach.

That history changed decisively in 2026. In a large, late-stage clinical trial called RASolute 302, Revolution Medicines’ oral drug daraxonrasib nearly doubled median overall survival among patients with metastatic pancreatic cancer compared with chemotherapy. On August 26, 2026, the FDA approved daraxonrasib, under the brand name Rasonque, for adults with metastatic pancreatic adenocarcinoma—the most common type of pancreatic cancer—who had received at least one prior systemic therapy or were not candidates for multiagent systemic therapy.

Rasonque is the first approved drug from Revolution Medicines’ new class of RAS(ON) inhibitors and the first approved targeted medicine designed to shut down a broad range of active RAS proteins in metastatic pancreatic cancer. Notably, the approved use doesn’t require a companion diagnostic test—the separate laboratory test required for some mutation-specific cancer drugs to establish that a tumor carries the targeted genetic variant. Rasonque’s label covers eligible patients with or without an identified RAS mutation, an important distinction from mutation-specific KRAS drugs. Doctors may still perform broad molecular testing to help guide a patient’s overall treatment.

This update folds the original explanation of RAS and KRAS into events that have happened since: the approval, the finalized efficacy and safety data, the commercial launch, new lung-cancer data, and the risks embedded in RVMD’s valuation.

Review: What Are RAS and KRAS?

Cells need signals telling them when to grow, divide, repair themselves, and stop growing. The RAS family of proteins helps transmit those signals. You can think of a RAS protein as a molecular switch inside the cell.

A RAS protein switches between two states. When it is bound to a molecule called GTP, RAS is active and transmits growth signals. RAS normally converts that GTP to a closely related molecule called GDP, returning the protein to its inactive state. Healthy cells continually cycle RAS between these states, turning the signal on only when needed and then shutting it off. Cancer-causing mutations interfere with that control system, causing RAS to remain active too often or too long and sending excessive signals that help cancer cells grow and survive.

Normally, RAS turns on in response to a growth signal and then turns back off. Cancer-causing mutations can keep RAS switched on too often or for too long, producing a steady stream of signals telling the cell to grow and survive. These are often called “driver mutations”—they help cause and sustain the cancer rather than just riding along with it.

Why RAS Was Considered “Undruggable”

Many drugs work by fitting into a pocket on a disease-causing protein and blocking its activity—imagine a key fitting into a lock and jamming it shut. RAS has a relatively smooth surface and binds tightly to its natural partners, leaving few obvious grooves for a drug to grab onto. Researchers understood RAS’s role in cancer for decades before anyone found a workable way to inhibit it.

The first major successes targeted one specific KRAS variant, called G12C—Amgen’s Lumakras and the drug Bristol Myers Squibb sells as Krazati. Those drugs proved that KRAS could be targeted, but only in tumors carrying that particular mutation. G12C matters considerably in lung cancer, but it represents a small share of pancreatic cancers, where variants called G12D, G12V, and G12R are much more common.

What Do Mutation Names Like G12C, G12D, and G12V Mean?

Proteins are chains of building blocks called amino acids, and the mutation shorthand identifies the original amino acid, its position in the chain, and the amino acid that replaced it.

A drug designed for one variant doesn’t automatically work against another—which is exactly why Revolution Medicines’ broader approach matters. Daraxonrasib isn’t confined to a single KRAS mutation. In laboratory studies, it inhibited active forms of mutant KRAS, NRAS, and HRAS, as well as the normal, unmutated—or “wild-type”—versions of these proteins.

Why Pancreatic Cancer Matters So Much

Pancreatic cancer is one of the deadliest common cancers—often caught late, aggressive in its progression, and historically thin on options once first-line chemotherapy stops working. Approximately 80% of patients are diagnosed after the disease has spread, and the U.S. five-year relative survival rate for metastatic pancreatic ductal adenocarcinoma is roughly 3%.

Its biology is what makes RAS so central: about 90% of pancreatic ductal adenocarcinomas, or PDAC—the most common form of pancreatic cancer—carry a KRAS mutation. A broad RAS inhibitor therefore has the potential to attack a central engine of the cancer rather than relying solely on chemotherapy’s less selective attack on rapidly dividing cells.

RAS alterations also appear in meaningful shares of lung, colorectal, and several less common cancers, although estimates vary by tumor subtype, patient population, and testing method. That is the basis for a commercial opportunity extending beyond pancreatic cancer if later trials succeed—but those additional uses remain unapproved and, in most cases, unproven in randomized Phase 3 trials.

These ranges are broad estimates from heterogeneous tumor series, not estimates of the number of patients who would necessarily respond to daraxonrasib. RAS alterations also occur in several less common cancers, but their frequency varies substantially by tumor subtype.

What Is Daraxonrasib, Now Rasonque?

Daraxonrasib—formerly known by its research name RMC-6236 and now sold as Rasonque—is an oral drug described as a “RAS(ON) multi-selective tri-complex inhibitor.” Broken down, “RAS(ON)” means that it targets RAS in its active, GTP-bound state. “Multi-selective” means that it is designed to inhibit multiple forms of RAS rather than a single mutation.

The mechanism is genuinely unusual, and it is worth understanding because it is central to why this drug worked where others stalled. According to the FDA-approved prescribing information, daraxonrasib first binds to a separate protein called cyclophilin A, which normally helps other proteins fold into their correct shape. That two-part combination then binds active RAS, forming a three-part cluster—hence “tri-complex”—that blocks RAS from interacting with downstream proteins and promotes its conversion toward the inactive, GDP-bound state. In laboratory studies, this approach inhibited mutant and normal forms of KRAS, NRAS, and HRAS—the broad reach that sets it apart from the first-generation, single-mutation G12C drugs.

The recommended dose is 300 mg by mouth once daily, with or without food, continued until the disease progresses or side effects become unacceptable. The label calls for beginning preventive skin care before the first dose because skin reactions are so common—worth knowing before getting to the safety data below.

The Phase 3 Results Behind the Approval

RASolute 302 was a global, randomized, open-label trial of 500 patients whose metastatic pancreatic adenocarcinoma had progressed after one prior line of systemic therapy. Patients were randomly assigned to Rasonque or their physician’s choice among several standard chemotherapy regimens. Because assignment was determined by chance, the groups could be compared more fairly. Patients and doctors knew which treatment each patient received, but tumor scans used to determine progression and response were assessed through a blinded independent review. The FDA-approved use is somewhat broader, also covering patients who are not candidates for multiagent systemic therapy.

All of these differences were statistically significant, making them extremely unlikely to be due to chance. “A 60% lower risk of death” describes the relative rate at which deaths occurred during the study—it doesn’t mean that 60% more patients were cured. Likewise, median survival is the point at which half of a treatment group was still alive, not a prediction for any one patient.

In the prespecified subgroup of patients with a RAS G12 mutation, the benefit was similarly strong: median overall survival was 13.2 months versus 6.6 months, progression-free survival was 7.3 months versus 3.5 months, and the objective response rate was 32% versus 11%. The trial also tracked quality of life directly: the median time before patients’ overall health noticeably worsened was 5.7 months with Rasonque versus 2.6 months with chemotherapy, while the median time before their pain worsened was 9.2 months versus 3.8 months—meaningful differences in a disease with such a heavy symptom burden.

The Safety Profile Needs Careful Description

Rasonque was easier on blood counts and nerve function than the chemotherapy comparator, but “targeted” doesn’t mean mild. The initial trial publication reported treatment-related rash in 85.5% of patients, diarrhea in 58.1%, and stomatitis in approximately 53%. In the final FDA label, which reports adverse reactions using somewhat different definitions, rash occurred in 87% of Rasonque-treated patients and was Grade 3 or 4 in 13%. Diarrhea occurred in 67%, stomatitis in 56%, nausea in 52%, and fatigue in 47%.

Grade 3 or higher treatment-related adverse events occurred in 43.6% of patients receiving Rasonque, compared with 57.5% receiving chemotherapy. Treatment-related events caused permanent discontinuation in 1.2% versus 11.2%, respectively. Using the FDA label’s broader measure, which includes all adverse reactions rather than only those attributed to treatment, 2.9% of Rasonque patients discontinued permanently. Dose management was common: adverse reactions caused temporary interruptions in 69% of patients and dose reductions in 37%. Taken together, the results suggest that Rasonque was generally more tolerable than chemotherapy, but often required active management.

The label also carries warnings for skin and soft-tissue reactions, mouth sores, diarrhea, a tear in the wall of the stomach or intestine—gastrointestinal perforation—inflammation of the lungs—interstitial lung disease or pneumonitis—and harm to a developing fetus. Gastrointestinal perforation occurred in 0.9% of patients across the pancreatic-cancer clinical program, including one fatal case, while interstitial lung disease or pneumonitis occurred in 2.4%, also including one fatal case. These are uncommon events, but they belong in any honest description of the drug and help explain why treatment requires active monitoring.

From Trial Data to Commercial Launch

Revolution Medicines set Rasonque’s list price—technically its wholesale acquisition cost, or sticker price before rebates and negotiated discounts—at $39,800 for a 30-day supply, or approximately $477,600 for twelve months. What insurers, government programs, and patients actually pay can be substantially different once rebates, discounts, coverage rules, and assistance programs come into play. Nevertheless, the list price is steep even by oncology standards and creates real reimbursement and access risk.

Working in the drug’s favor are a large survival benefit, once-daily pill dosing instead of intravenous chemotherapy, no required companion diagnostic, and a scarcity of effective options once first-line chemotherapy fails—all factors that strengthen its case with doctors and insurers despite the price.

How the Market Reacted—and What the Valuation Assumes

RVMD shares had already risen sharply after the positive trial data were announced in the spring, so the muted response to the August approval wasn’t evidence that the approval didn’t matter. It was evidence that investors had largely anticipated it. By the close on September 4, 2026, the stock was around $210 and the company’s market capitalization—the total value of all its shares—was approximately $44 billion.

That is a striking valuation for a company just beginning its first commercial launch, and it reflects expectations well beyond the currently approved use. Earlier-line pancreatic cancer, lung cancer, and potentially other RAS-driven tumors are all incorporated into the valuation to some degree.

The balance sheet gives Revolution Medicines substantial room to pursue that ambition. The company reported approximately $3.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. Spending is also substantial: 2026 GAAP operating-expense guidance is $2.1 billion to $2.2 billion, and the net loss for the first six months was approximately $1.10 billion. That loss included a $166.8 million noncash accounting charge from changes in the value of warrants assumed in the company’s earlier acquisition of EQRx. These reported figures provide a firmer foundation than short-term revenue estimates, which can change quickly now that Rasonque is on the market.

CEO Mark Goldsmith and other insiders have sold shares, including through prearranged Rule 10b5-1 trading plans—a common and legal mechanism that allows executives to schedule transactions in advance. Scheduled selling can weigh on investor sentiment, but it doesn’t by itself establish that management expects the business to deteriorate. The plan-adoption date, transaction size relative to the executive’s remaining holdings, and longer-term pattern are more informative than any single sale.

Competition: Important, but Not Every Rival Treats the Same Patients

Amgen’s Lumakras (sotorasib) and Bristol Myers Squibb’s Krazati (adagrasib) are approved KRAS G12C inhibitors. They proved that KRAS could be drugged but work only in tumors carrying that particular mutation. Roche’s divarasib, another G12C-targeted drug in late-stage development, has reported a head-to-head Phase 3 win against both approved G12C drugs in lung cancer.

These are real competitors, but not for every patient daraxonrasib is intended to address. The published lung-cancer data discussed below excluded G12C-mutant tumors, and the ongoing Phase 3 lung-cancer trial’s core population is built around other G12-family mutations—a setting in which there is currently no approved mutation-targeted RAS therapy. Divarasib is more directly relevant to Revolution Medicines’ G12C-specific drug candidate, elironrasib, and to any future daraxonrasib strategy that includes G12C disease.

Beyond Pancreatic Cancer: Encouraging Lung Data, Not Yet Proof

On September 2, 2026, The New England Journal of Medicine published Phase 1/2 results for daraxonrasib in previously treated RAS-mutant non-small cell lung cancer, the most common category of lung cancer. The study included 136 patients with RAS mutations other than G12C whose cancer had progressed after, or who could not tolerate, platinum-based chemotherapy and anti-PD-(L)1 immunotherapy.

The most encouraging numbers came from a smaller, clinically defined subgroup of 38 docetaxel-naive patients treated at doses of 160 to 220 mg, below the approved 300 mg pancreatic-cancer dose. In that subgroup, 42% of patients had a confirmed tumor response, 89% achieved disease control, median progression-free survival was 8.3 months, and median overall survival was 16.0 months. These results are promising, but a small, nonrandomized subgroup cannot provide the same level of evidence as a randomized Phase 3 trial.

Those data helped support RASolve 301, the ongoing randomized Phase 3 trial comparing daraxonrasib with docetaxel in previously treated RAS-mutant lung cancer. A positive result could meaningfully expand the drug’s market. A disappointing result would undermine part of the growth already incorporated into RVMD’s stock price.

The Rest of Revolution Medicines’ RAS Pipeline

The portfolio gives Revolution Medicines multiple ways to attack RAS-driven cancer—a broad drug covering multiple mutations, plus narrower drugs optimized for individual ones. It is a coherent strategy, but the follow-on drugs remain investigational and shouldn’t be treated as sure things.

What This Means for Investors

RVMD remains an event-driven biotechnology stock even with one approval secured. The variables that matter most from here include how smoothly the Rasonque launch proceeds, whether insurers provide broad coverage, how the drug performs in wider clinical use, progress in earlier-line pancreatic cancer, and the outcome of the lung-cancer trial.

For options traders, RVMD remains a potentially volatile, event-driven stock. As of this writing, implied volatility is around 47%, while its IV rank is near the lower end of RVMD’s one-year range. That means option-implied volatility is relatively low compared with the stock’s own recent history, although it does not necessarily make every contract inexpensive. The company’s next earnings report is currently estimated for early November, but Revolution Medicines has not yet announced the date. Earnings and future clinical news could move the shares substantially in either direction, while option prices, volatility, and analyst expectations can change quickly.

The Risks

Rasonque’s approval substantially reduces Revolution Medicines’ scientific and regulatory risk in one specific setting, but it doesn’t remove commercial or pipeline risk. The launch could be slowed by insurance restrictions, the demands of managing side effects, or the drug’s high list price. Rash, mouth sores, and diarrhea are common, and the rarer gastrointestinal and lung toxicities, while uncommon, are real.

Success in previously treated metastatic pancreatic cancer doesn’t guarantee success in earlier treatment lines, lung cancer, or colorectal cancer. Competition will also differ by mutation: Roche’s divarasib and the established G12C drugs are most directly relevant to G12C disease and to Revolution Medicines’ G12C-selective candidate elironrasib, while other companies are developing drugs against additional RAS mutations and broader RAS pathways. Targeted drugs can also lose effectiveness as tumors evolve resistance, and combination treatments may add toxicity or fail to improve outcomes.

A market capitalization of approximately $44 billion already assumes a great deal of future success. Even genuinely good news can produce a muted stock reaction if the market saw it coming—as happened when the approval produced little additional lift—while slower-than-expected uptake or a disappointing lung-cancer trial could force investors to remove value already incorporated into the share price.

Bottom Line

Revolution Medicines has achieved a genuine scientific and clinical milestone: it turned a broad approach to inhibiting active RAS into an FDA-approved treatment that nearly doubled median overall survival in a rigorous, randomized trial of metastatic pancreatic cancer. Patients also went longer before their cancer progressed and experienced meaningful delays before their overall health and pain worsened. Although side effects were common and frequently required active management, relatively few patients stopped treatment permanently because of them.

The bullish case is that Rasonque becomes an important pancreatic-cancer treatment and validates a platform that expands into other RAS-driven cancers. The cautionary case is that RVMD’s valuation already assumes more than one successful use. The first approval is now secured; what remains to be demonstrated is how well Revolution Medicines executes the launch and whether randomized trials can reproduce the platform’s promise in lung cancer and additional pancreatic-cancer settings.

Sources

• FDA—Daraxonrasib Approval Notice
• FDA—First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
• Rasonque Full Prescribing Information
• Revolution Medicines—Rasonque Approval and RASolute 302 Results
• Published Phase 3 RASolute 302 Study
• Revolution Medicines Form 8-K—Approval and Wholesale Acquisition Cost
• Revolution Medicines—Second-Quarter 2026 Financial Results
• New England Journal of Medicine—Phase 1/2 Daraxonrasib Study in RAS-Mutant NSCLC
• ClinicalTrials.gov—RASolve 301
• Reuters—Pancreatic-Cancer Trial Results and Quality of Life
• Fierce Biotech—Roche Divarasib Phase 3 Results
• Barchart—RVMD Options Data
• Original PSW Article—Revolution Medicines, Daraxonrasib, and the New Race to Drug KRAS Cancer